Rapid antigen detection diagnostic tests (RDTs) are more widely accessible than expert microscopy, provide prompt results and are adequately sensitive for Plasmodium falciparum infections. However, RDTs cannot quantify parasite density (so do not detect hyperparasitaemia that indicates severe malaria) and are less sensitive for non-falciparum species than for falciparum infections. RDTs are unsuitable for monitoring treatment response because of antigen persistence. [4] A negative (rapid or microscopy) test does not exclude malaria; repeat testing within 8 -24 hours, without attempting to coincide with fever peak timing, is mandatory until a positive result or an alternative definitive diagnosis is achieved. Blood smears should be checked for malaria whenever thrombocytopenia is unexpectedly identified. Test any patient with unexplained fever for malaria, even in the absence of a travel history. Occasionally, infected mosquitoes are transported from endemic areas in suitcases and vehicles (Odyssean malaria). [5] All malaria cases must be notified to local health authorities.
Treatment of malaria
The choice and route of treatment depends primarily on disease severity, which is often underestimated. Uncomplicated malaria is symptomatic infection without signs of severity or evidence of vital organ dysfunction. Persistent vomiting, clinical jaundice, change in mental state or increase in respiratory rate constitutes severe malaria (Table 2) . [6, 7] Treat uncomplicated malaria with artemether-lumefantrine (Coartem) ( Table 3) . [2] For optimal absorption it must be taken with milk or fat-containing food. Adequate fluids, temperature control with paracetamol, and careful follow-up are important. Avoid non-steroidal anti-inflammatory agents. Patients should respond clinically and parasitologically within 24 -48 hours. Consider poor compliance, misdiagnosis and possible drug resistance if no significant improvement occurs within 72 hours. Artemetherlumefantrine remains efficacious in South Africa (SA), [8, 9] with no reports of artemisinin resistance in Africa as yet. In the rare event of artemether-lumefantrine treatment failure despite full compliance, give a full directly observed 7-day course of oral quinine (plus doxycycline or clindamycin) in hospital.
Oral quinine, combined with 7 days of doxycycline, remains an alternative to artemether-lumefantrine (Table 4 ), but compliance is poor. In pregnancy or children aged <8 years, substitute clindamycin for doxycycline ( Keep a high index of suspicion for malaria in travellers to, or residents of, malaria transmission areas presenting with fever or other 'flu-like illness, irrespective of the time of year, intensity of transmission or use of chemoprophylaxis. Always take an adequate travel history.
Typical presentation: paroxysms of fever and rigors in adults, also headache, myalgia, loss of appetite, nausea and vomiting. In young children, fever, lethargy, poor feeding, vomiting and diarrhoea are most common.
Important differential diagnoses: meningitis, African tick-bite fever, typhoid, viral haemorrhagic fever, trypanosomiasis.
Progression to severe disease may be rapid, particularly in non-immune and immune-compromised persons, young children and pregnant women.
Often missed in patients with comorbid disease.
Frequently misdiagnosed in pregnancy, requiring differentiation from pregnancy complications including intrauterine and urinary tract infections. treatment benefit, so are started only once symptoms improve, as gastrointestinal side-effects may exacerbate those of quinine.
Drug interactions
Concomitant use of certain other drugs (e.g. efavirenz, rifampicin) may alter blood concentrations of artemether-lumefantrine and quinine. There is no evidence of the clinical significance of these interactions, but full adherence and fat co-administration is advised, and response to treatment should be monitored particularly carefully.
Pregnancy
First trimester. Supervised 7-day course of oral quinine plus clindamycin.
Second and third trimesters. Artemether-lumefantrine is considered safe and efficacious.
Large adults
Artemether-lumefantrine is registered in SA only for use in patients weighing ≤65 kg. Minimal pharmacokinetic data exist for larger patients; one study suggests a trend towards increased risk of treatment failure in patients >80 kg. [10] Again, adequate adherence and fat co-administration is important, with careful monitoring of response. If adherence is assured, consider administering the same total dose over 5 days (dosing at 0, 8, 24, 48, 72 and 96 hours).
Recommendations for non-falciparum malaria
Malaria species should be confirmed by a reliable laboratory. Nonfalciparum infections are usually uncomplicated, but occasionally produce severe illness. Use artemether-lumefantrine for initial therapy of uncomplicated P. vivax and P. ovale infections. To prevent relapses, this should be followed by a course of primaquine after excluding glucose-6-phosphate dehydrogenase (G6PD) deficiency. The recommended dose in children is 0.25 -0.3 mg/kg daily for 14 days, and that for adults is 15 mg daily for 14 days. Currently primaquine is only available on a named-patient basis with Section 21 MCC approval.
Severe malaria (Table 5) Severe malaria is a medical emergency requiring prompt parenteral treatment, intensive nursing care, and careful monitoring and management of complications. [6.7] Intravenous artesunate (2.4 mg/kg Now recommended for all trimesters [12, 13] if travel is necessary.
Contraindicated
Contraindicated owing to lack of data.
Young children -avoid taking children <5 years to high-risk areas.
Can be used in children >3 months or >5 kg. Generally well tolerated by children.
Use only in children >8 years. Paediatric tablets can be given to children >11 kg. Breaking of tablets is not recommended.
Persons requiring long-term prophylaxis
Can be used for up to 3 years. Longer-term use may be justified by risk of malaria.
Can be safely used for up to 2 years. Longer term use may be justified by risk of malaria.
Can be used confidently for up to 1 year. Longer-term use may be justified by risk of malaria.
HIV-positive (on ARVs) Best option ARVs = antiretrovirals.
Fig. 1. Malaria risk map for SA (adopted 2014).
at 0, 12 and 24 hours, then daily until the patient is able to tolerate oral treatment) is preferred treatment, but is currently unregistered and only available on a named-patient basis with Section 21 MCC approval. [2, 11] When intravenous artesunate is not promptly available, intravenous quinine (with an initial loading dose of 20 mg/kg and then maintenance doses of 10 mg/kg, each dose slowly infused over at least 4 hours) is initiated urgently and given 8-hourly until oral treatment is tolerated. Follow with a complete course of artemetherlumefantrine. [2] Reassess frequently to ensure that all complications are promptly detected and optimally managed.
Critical issues in management of severe malaria
Hypoglycaemia. Urgently exclude (or administer empiric glucose) if there is a depressed level of consciousness or convulsions. Repeat glucose monitoring 4-hourly.
Renal failure. This is a frequent, early complication in adults. Severe malaria requires careful fluid management, with frequent measurement of renal function (urea, electrolytes and creatinine), ongoing monitoring of urine output and judicious fluid administration. Strictly avoid overhydration, as the acute respiratory distress syndrome is a common and difficult-to-treat complication, particularly in pregnancy.
Prevention of malaria
Prevention of mosquito bites is the mainstay of malaria prevention. Malaria-transmitting mosquitoes generally bite at night, so people in malaria-endemic areas should ideally remain indoors from dusk to dawn, and sleep under insecticide-treated bednets in rooms with screened windows and doors. Fig. 1 shows endemic areas in SA; residents and travellers in these areas should take necessary precautions to avoid mosquito bites.
Effective repellents contain DEET (diethyl toluamide). Use products containing 20 -50% DEET for long-lasting protection for adults and children aged >2 months. Products containing >50% DEET have no additional benefit. Avoid applying to eyes or mouth.
Additionally, travellers to malaria-endemic areas should use chemoprophylaxis depending on the malaria risk assessment. Three similarly effective chemoprophylactic agents are currently registered in SA (Table 5 ), all requiring a doctor's prescription. Selection should be based on patient factors (Table 6 ) and which option is likely to be best tolerated for optimal adherence.
Scope of protection
Chemoprophylactics are most effective against parasite asexual blood stages. While they will prevent initial illness caused by all species, they will not prevent relapses due to P. vivax and P. ovale.
